



# Cortellis Competitive Intelligence ウェブセミナー

基本編：世界の医薬品と特許情報をもれなく収集する

# 本日の紹介内容

## 1. Cortellis Competitive Intelligence コンテンツ基本解説

- Cortellisがカバーする医薬品情報について
- 医薬品レポート徹底解説

(市場予測、製品売上実績/予測、開発イベント履歴、安全性情報等)

## 2. MOA、技術、疾患軸からパイプライン情報を網羅的に整理するには？

- 開発動向をアラート機能でモニターする
- 開発情報一覧を外部出力する
- 検索結果から開発傾向を分析する

## 3. 特定の開発品や創薬技術に関連した特許の現状と傾向を分析するには？

- 特許レポート徹底解説
- 特許出願数の年次推移分析から注目の技術領域を確認する

## 4. BIツールを活用した分析事例

- パイプライン全体像分析機能 Competitive Landscape Viewer
- ポートフォリオ分析機能 Virtual Merger

# Competitive Intelligence コンテンツ基本解説

- Cortellisがカバーする医薬品情報について
- 医薬品レポート徹底解説


# 医薬品開発における課題解決・意思決定をサポートする 情報プラットフォームCortellis

Drug Discovery  
INTELLIGENCE  
生理活性物質情報  
ソリューション


プレスリリース&  
ニュース  
企業等のウェブサ  
イト&出版物  
会議・文献・特許  
世界中の臨床試験  
レジストリ  
規制当局  
...and More



- 信頼性のある情報を網羅的にタイムリーに取得できます
- 公開情報の個別調査では得られない情報・知見を提供します



# 医薬品競合情報の包括的な収集・分析をワンストップで実現する多彩なコンテンツと可視化・分析機能



90K+  
医薬品パイプライン



5.6M+  
特許ファミリー



2.7M+  
開発医薬品  
関連文献



260K+  
企業



1,400+ 医薬品のSWOT分析



89 k +  
契約レコード



一か所でより多くの情報を

早期パイプラインやオーファンドラグなど、より完全な情報にアクセスして競合優位性を維持



ワークフローをシンプルに

単一のプラットフォーム上に統合された網羅的なパイプライン情報と分析機能で分析を簡単に



全世界を網羅

100カ国以上における医薬品開発プログラムや企業情報にアクセス



独自コンテンツ

ブローカーリサーチやSWOT分析など独自コンテンツを活用してアセットや競合の理解を完璧に



より高い精度で今後を予測

Drug Timeline & Success Ratesの機械学習分析により開発パイプラインの動向予測精度を25%向上

## Cortellis Competitive Intelligence

ポートフォリオ戦略のための  
正確かつ網羅的な医薬品競合  
情報

代表的活用シーン

- 疾患・作用機序・技術から競合全体を分析
- 自社品の差別化
- 競合アセットの開発ベンチマーク
- 開発タイムライン・成功確率予測
- 創薬基盤技術・開発技術特許の動向分析
- 提携候補先のデューデリジェンス
- 開発領域の市場性評価
- and more...

## 収録対象医薬品の種類

1994年以降に開発が始まり、商業的に開発可能性のあるパイプラインとして公に発表された医薬品を収録しています。  
(一部の主要医薬品は1994年以前も遡及収録) 前臨床段階の開発品から上市済み製品まで全てのステージをカバーしています。

### レコード作成対象


商業的に開発/販売されている前臨床開発品・治験薬・承認薬  
(AGは対象外だが、biosimilar/bio-same等のFOBは収録対象)

### レコード作成対象外


OTC、化粧品、洗口剤、動物薬、移植、  
医療機器全般(一般医療機、放射線機・画像診断機器、生命維持装置、歯科治療機器、一般手術用機器)、  
体外診断用医薬品、サプリ、ビタミン剤、酸化防止剤、漢方製剤、全身麻酔薬、代用血液、メディカルアプリ

# パイプライン開発の差別化に必要な独自の分析を入手


- 参入候補市場を疾患領域から分析する
- SWOT分析を用いて製品理解を深める
- 開発関連イベントの進捗をタイムラインと合わせて確認する
- 安全性情報から開発品の評価を実施する



SWOT分析



市場推移予測データ



開発イベントマイルストーン




安全性情報MAP

# Drug Report

## Market landscape

- CortellisとDRGソリューション(Disease Landscape & Forecast) 連携データの活用
- 疾患の全体像と10年先までの市場推移を加味した売上予測データから市場サイズを把握
- 治療対象患者人口の特性と相対的規模を同定
- 市場リーダーの動向モニターおよび市場に大きな影響を与える革新的治療の探索
- 市場において最も有望な薬物群およびその作用機作を探索



# Drug Report

## Safety Intelligence

安全性の面から迅速な先行品ベンチマークや開発品評価が可能に

- Heatmap

System Organ Class毎の有害事象報告を把握

- Comparative Evidence


類薬と安全性プロファイルを比較

- Latest Safety Alert

最新の有害事象報告

安全性情報統合データベースOFF-Xによる

医薬品・治験薬に関する安全性情報とその分析を提供



## MOA・技術・疾患軸からパイプライン情報を網羅的に整理する

- 開発動向をアラート機能でモニターする
- 開発情報一覧を外部出力する
- 検索結果から開発傾向を分析する

# Indication(疾患) やAction (MOA) 索引の活用

※索引例:Indications-Retinopathy、Actions-AAV

SHOW ALL FILTERS

retinopathy

☐ Non-Hierarchical List  
☒ Hierarchical List

Company  
Principal Company  
Principal Company HQ  
Principal Company Type  
Partner Company  
Partner Company HQ  
Partner Company Type  
Principal Company Field of Activity  
Partner Company Field of Activity

**Indications**

Therapy Area  
Technologies  
Target-based Actions  
Other Actions  
Territories Included

☒ Ocular disease (3058)  
☒ Retinopathy (1035)  
☒ Age related macular degeneration (553)  
☒ Wet age related macular degeneration (101)  
☒ Dry age related macular degeneration (62)  
☒ Diabetic retinopathy (243)  
☒ Diabetic macular edema (114)  
☒ Non-proliferative diabetic retinopathy (3)  
☒ Proliferative diabetic retinopathy (2)  
☒ Macular disease (187)  
☒ Macular edema (130)  
☒ Diabetic macular edema (114)  
☒ Macular degeneration (27)  
☒ Stargardt disease (23)  
☒ Vitelliform macular dystrophy (3)  
☒ Best macular dystrophy (3)  
☒ Retinal edema (130)  
☒ Macular edema (130)  
☒ Diabetic macular edema (114)  
☒ Retinitis pigmentosa (107)  
☒ Fabry disease (44)

SHOW ALL FILTERS

adeno-associated virus b

☐ Non-Hierarchical List  
☒ Hierarchical List

Company  
Principal Company  
Principal Company HQ  
Principal Company Type  
Partner Company  
Partner Company HQ  
Partner Company Type  
Principal Company Field of Activity  
Partner Company Field of Activity



**Any Actions**

Territories Included  
Territories Excluded

☒ Genetic modulator (4181)  
☒ Gene therapy (4176)  
☒ Viral vector based gene therapy (1145)  
☒ Adeno-associated virus based gene therapy (616)  
☐ Adenovirus based gene therapy (259)  
☐ Herpes virus based gene therapy (28)  
☐ Retrovirus based gene therapy (141)  
☐ Unspecified virus based gene therapy (40)  
☐ Genetically engineered autologous cell therapy (674)  
☐ RNA interference agent (641)  
☐ DNA vaccine (521)  
☐ Antisense oligonucleotide inhibitor (346)  
☐ Non-viral vector based gene therapy (230)  
☐ Unspecified vector based gene therapy (50)  
☐ Oncogene inhibitor (24)  
☐ Immunomodulator (19674)  
☐ Musculoskeletal system modulator (903)  
☐ Ophthalmological agent (1091)  
☐ Other actions (5722)  
☐ Pathway modulator (10512)  
☐ Protein target (20255)

Filter設定をHierarchical Listに変更すると、検索タームの上位・下位の統制語エリアを確認可能  
→希望の検索タームにチェックが入っていれば適切にFilterが設定されています。  
検索ボックスに入力した検索スペルと完全一致したタームが選択されます。

# Download機能



| Drug Name                                        | Active Indications                       | Target-based Actions                    | Technologies                            | Structure |
|--------------------------------------------------|------------------------------------------|-----------------------------------------|-----------------------------------------|-----------|
| 1. <a href="#">Lisdexamfetamine dimesylate</a>   | Attention deficit hyperactivity disorder | Neurotransmitter transporter inhibitors | Neurotransmitter transporter inhibitors |           |
| 2. <a href="#">Methylphenidate hydrochloride</a> | Attention deficit hyperactivity disorder | Dopamine reuptake inhibitors            | Dopamine reuptake inhibitors            |           |
| 3. <a href="#">Amphetamine</a>                   | Attention deficit hyperactivity disorder | Dopamine reuptake inhibitors            | Dopamine reuptake inhibitors            |           |
| 4. <a href="#">Methylphenidate</a>               | Attention deficit hyperactivity disorder | Dopamine reuptake inhibitors            | Dopamine reuptake inhibitors            |           |

Download機能から検索条件に合致したパイプライン情報一覧をExcel形式等で出力可能



Customized Result形式出力では、必要な統制語エリアの情報を限定して出力が可能

# Alert機能

STEP1: Save and Alertをクリックし、Save and alert on search queryを選択し検索クエリにAlertを設定する  
↓  
STEP2: Alert名の設定、検索式の確認  
↓  
STEP3: Updateを受け取る内容を選択、新たなパイプラインの出現をモニターする際にはStatusにチェック  
↓  
STEP4: Alertを受け取る頻度を設定

SAVE SEARCH AND/OR ALERT

Choose if you would like to save the search query or reports, create an alert, or save and alert combined, based on the search query (including filters) or reports in the results list

Save search query

Alert on search query

**Save and alert on search query**

Save reports

Alert on reports

Save and alert on reports

Step 1 Step 2 Step 3 Step 4

SAVE SEARCH AND ALERT

Enter a preferred name, or just click Next to use the displayed name.

Name

endometriosis 25-Sep-2019 17:04

Search Query

endometriosis

Includes

18 Filter(s)

Cancel Previous Next

## Alert updates...

- ☐ Select All
- ☐ Chemistry
  - ☐ Development Profile
  - ☒ Development Status
  - ☐ Drug Name
  - ☐ Index
- ☐ Alert me if there are no updates

## Step 1 Step 2

### FORMAT, START DATE AND FREQUENCY

Choose your preferred alert format, when you would like to receive updates

#### Email format

- ☒ HTML
- ☐ Text

#### Start date of alert


- ☒ Earliest available date ()
- ☐ Specify date

#### Frequency


- Daily
- Daily
- Weekly
- Monthly

☐ I would like to share this alert with colleagues

# Alertの管理と検索式の保存



Searches and alertsから、これまでに設定したアラートの確認、On/Off切替え、削除などができます。Run Searchをクリックすると、保存された検索条件に該当するレコード得結果を得ることができます。



特定の開発品や創薬技術に関連した特許を分析する

- 特許レポート徹底解説

- 特許出願数の年次推移分析から注目の技術領域を確認する

# Competitive Intelligence 特許レポート特徴

| Snapshot             | Highlight <input type="checkbox"/> Search Terms & Synonyms | < Previous                                                                                                                                                                                                                                                                      | Next > |
|----------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Companies and Drugs  | SNAPSHOT                                                   |                                                                                                                                                                                                                                                                                 |        |
| Editorial Abstract   | Patent Number                                              | WO-09613266                                                                                                                                                                                                                                                                     |        |
| Chemical Structures  | Title                                                      | Boronic ester and acid compounds, synthesis and uses.                                                                                                                                                                                                                           |        |
| Claims               | Original Assignee                                          | PROSCRIPT, INC.                                                                                                                                                                                                                                                                 |        |
| Documents and Status | Inventor Abstract                                          | Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses. |        |
| Expiry               | Patent Type                                                | Product (Macromolecule); Product                                                                                                                                                                                                                                                |        |
|                      | Indications                                                | HIV infection; Inflammatory disease; Arthritis; Carcinoma                                                                                                                                                                                                                       |        |
|                      | Target-based Actions                                       | Nuclear factor kappa B inhibitor; Proteasome inhibitor                                                                                                                                                                                                                          |        |
|                      | Other Actions                                              | Apoptosis modulator; Anticancer                                                                                                                                                                                                                                                 |        |
|                      | Technologies                                               |                                                                                                                                                                                                                                                                                 |        |

|            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Annotation | <p><b>WO-2014181888</b><br/>Method for producing peptides and peptide libraries using the codon reassignment in mRNA and tRNA; and a method for screening for peptides that binds to target sequences in mRNA during reverse transcription using RT-PCR. Apparently, this is the first joint filing from the assignees; and is based on PeptiDream's Translation, Cyclization, and Peptide-Modifying Technology. Refer <a href="#">WO2014119600</a> for a similar previous filing from Murakami, Reid and Sasaki. At the time of this publication, Kawakami appears to be affiliated to Osaka University; and Sasaki appears to be affiliated to Okayama University. Covers PeptiDream's proprietary PD Platform, a highly versatile peptide generation and selection platform, based on three core technologies (a) Flexizyme, (b) translation, cyclization, and peptide modifying technologies, and (c) PD display. In August 2010, PeptiDream agreed to identify nonstandard macrocyclic peptides using its Peptide Discovery Platform System (PDPS) technology for Novartis' targets. In December 2012 and October 2014, the agreement was amendment and extended. In April 2015, PeptiDream announced that Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream's proprietary PDPS. Under this agreement, Novartis would pay undisclosed upfront payments, development milestones and royalties [1646895].</p> |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Drug report等と共通の統制語

- 医薬品特許の検索にあった統制語体系
- 特許の専門家でなくとも使いやすい

## 特許を商業的側面からまとめた Annotation

- 同じ発明者の類似出願→関連性の高い他の特許にアクセス
- 独占権情報を簡単に把握


# Competitive Intelligence 特許レポート特徴

|                      |                                                    |                                        |
|----------------------|----------------------------------------------------|----------------------------------------|
| Companies and Drugs  | COMPANIES AND DRUGS                                |                                        |
| ■ Companies          | COMPANIES                                          |                                        |
| ■ Drugs              | Owner Companies                                    |                                        |
| Editorial Abstract   | Company Name                                       | Relationship Type                      |
| Chemical Structures  | <a href="#">Ortho Biotech Products LP</a>          | Licensee for development and marketing |
| Claims               | <a href="#">Takeda Oncology</a>                    | Patent Assignee/Owner                  |
| Documents and Status | <a href="#">LeukoSite Inc</a>                      | Patent Assignee/Owner                  |
| Expiry               | <a href="#">Millennium Pharmaceuticals Ltd</a>     | Patent Assignee/Owner                  |
|                      | THIRD PARTY COMPANIES                              |                                        |
|                      | Company Name                                       | Relationship Type                      |
|                      | <a href="#">Teva Pharmaceutical Industries Ltd</a> | Patent opponent or infringer           |
|                      | <a href="#">Watson Pharma Private Ltd</a>          | Patent opponent or infringer           |
|                      | <a href="#">Sandoz Inc</a>                         | Patent opponent or infringer           |
|                      | <a href="#">Mylan NV</a>                           | Patent opponent or infringer           |
|                      | DRUGS                                              |                                        |
|                      | Owner Relationship                                 |                                        |
|                      | Drug Name                                          | Relationship Type                      |
|                      | <a href="#">MLN-273</a>                            | Product                                |
|                      | <a href="#">bortezomib</a>                         | Product                                |

## Companies and Drugs

- 出願人を含む関係組織をリスト
- 医薬品との関連性の索引を表示
- 競合医薬品の特許調査を容易に

# Competitive Intelligence 特許レポート特徴

| Summary Abstract        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Document Written From   | WO-09613266                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Enhanced Title          | Boronic ester and acid compounds, synthesis and uses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Abstract Classification | Pulmonary-Allergy, Dermatological and Anti-Inflammatory                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Novelty                 | Boronic ester and acid derivatives and pharmaceutical compositions are claimed. Also claimed are their methods of inhibiting the growth of a cancer cell, of reducing the rate of muscle protein degradation in a cell, of reducing the activity of NF- kappa B in a cell, of reducing the rate of intracellular protein breakdown, of reducing the rate of degradation of p53 protein in a cell, of inhibiting cyclin degradation in a cell, of preventing or treating inflammation, tissue or organ rejection, arthritis, infection, dermatoses, inflammatory bowel disease and autoimmune diseases, for inhibiting antigen presentation in a cell, for inhibiting inducible NF- kappa B dependant cell adhesion and for inhibiting HIV replication in an animal. |
| Advantage               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Biology                 | Assays described include inhibition of protein degradation in C2C12 cells, inhibition of corticosterone-induced cachexia in rats, inhibition of expression of cell adhesion molecules on HUVE cells and blocking of the DTH response in mice. Results are presented in six tables.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Examples                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Chemistry               | The specified compound, N-(pyrazolin-2-ylcarbonyl)-L-phenylalanine-L-leucine boronic acid (bortezomib), is one of nine derivatives specifically claimed and its preparation is described in one of 17 examples. A reaction scheme is depicted for the preparation of the compounds.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Compound Name           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Abstract Structure      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Summary Abstract

## Editorial Abstract

技術的な側面から作成した抄録

→研究者の方が競合の特許状況を把握するのに読みやすい。代表化合物は構造検索可能

# Competitive Intelligence 特許レポート特徴

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DWPI Abstract                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <div>FirstPrevious12345NextLast</div> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Document Written From                 | US-05780454                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Title                                 | New boronic acid derivatives useful as inhibitors of proteasomes in the treatment of e.g. organ rejection, arthritis, inflammatory bowel disease, multiple sclerosis and cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Novelty                               | Boronic acid derivatives of formula (I) and their salts are new: P 1 = R 7 CO, or R 7 SO 2 ; R 7 = pyrazinyl; R = H or alkyl; R 2 , R 3 = H, alkyl, cycloalkyl, aryl, or CH 2 R 5 ; R 5 = aryl, aralkyl, alkaryl, cycloalkyl, or W 1 R 6 ; W 1 = chalcogen; R 6 = alkyl; and Z 1 , Z 2 = OH, alkoxy, or aryloxy; or Z 1 + Z 2 = group derived from dihydroxy compound having ≥ 2 OH groups separated by ≥ 2 atoms in a carbon chain or ring optionally containing ≥ 1 of N, S, or O. The ring portion of aryl, aralkyl, or alkaryl in R 2 , R 3 , or R 5 is optionally substituted by 1-2 of 1-6C alkyl, 3-8C cycloalkyl, 1-6C alkyl(3-8C) cycloalkyl, 2-8C alkenyl, 2-8C alkynyl, CN, NH 2 , 1-6C alkylamino, di(1-6C)alkylamino, benzylamino, dibenzylamino, NO 2 , CO 2 H, carbo(1-6C)alkoxy, CF 3 , halo, 1-6C alkoxy, 6-10C aryl, 6-10C aryl(1-6C) alkyl, 6-10C aryl(1-6C) alkoxy, OH, 1-6C alkylthio, 1-6C alkylsulphinyl, 1-6C alkylsulphonyl, 6-10C arylthio, 6-10C arylsulphinyl, 6-10C arylsulphonyl, 1-6C alkyl(6-10C) aryl, or halo( 6-10C) aryl; NB. In a dependent claim, P 1 is defined as quinolinecarbonyl, pyridinecarbonyl, quinolinesulphonyl, quinoxalinecarbonyl, quinoxalinesulphonyl, furancarboxyl, furansulphonyl, or N-morpholinylcarbonyl. |
| Use                                   | USE<br>The compounds are inhibitors of proteasomes (claimed). They also inhibit transcription factor NF-κB, p53 protein degradation and cyclin degradation. They are useful for treating inflammatory conditions e.g tissue and organ rejection, arthritis, infection, dermatoses, inflammatory bowel disease, asthma, osteoporosis and osteoarthritis, cell proliferative diseases e.g. cancers, psoriasis, and restenosis, autoimmune diseases e.g. lupus and multiple sclerosis, accelerated muscle protein breakdown related to nerve injury, fasting fever, and acidosis, and other conditions like sepsis, AIDS and endocrinopathies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Advantage                             | ADVANTAGE<br>(I) are potent and highly selective.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Detailed Description                  | MORE SPECIFICALLY<br>R = H, or 1-8C alkyl; R 2 = isobutyl, 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(benzyloxy)benzyl, benzylmethyl, or phenethyl; Z 1 , Z 2 = OH, 1-6C alkoxy, 6-10 aryloxy, preferably OH; Z 1 + Z 2 = pinacol, perfluoropinacol, pinandiol, ethylene glycol, diethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol, or diethanolamine; and R 3 = 1-12C alkyl preferably isobutyl.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Activity                              | BIOLOGICAL ACTIVITY<br>Ear swelling induced by topical application of 2,4-dinitrofluorobenzene to sensitised mice was inhibited by 90% when (Ia) (3 mg/kg) was orally administered 30 minutes prior to challenge.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Mechanism of Action                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

## DWPI Abstract

- 特許専門家向け抄録  
→Summary Abstractが作られない場合に英語で内容把握できる
- 検索不可

# Competitive Intelligence 特許レポート特徴

Highlight ☐ Search Terms & Synonyms < Previous Next >

| DOCUMENTS AND STATUS            |           |                                                             |                 |                                                                                     |
|---------------------------------|-----------|-------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------|
| Family Patent WO-09613266 (1) ▼ |           |                                                             |                 |                                                                                     |
| Application Number              |           | Date                                                        |                 |                                                                                     |
| WO1995US14117                   |           | 27-Oct-1995                                                 |                 |                                                                                     |
| Priority Number                 |           | Date                                                        |                 |                                                                                     |
| US1994330525                    |           | 28-Oct-1994                                                 |                 |                                                                                     |
| US1995442581                    |           | 16-May-1995                                                 |                 |                                                                                     |
| Patent Number                   | Kind Code | Publication Date                                            | Number of Pages | PDF Document                                                                        |
| WO-09613266                     | A1        | 09-May-1996                                                 | 145             |  |
| Gazette Date                    | Code      | Description (remarks)                                       |                 |                                                                                     |
| 31-Dec-2004                     | WWG       | WIPO INFORMATION: GRANT IN NATIONAL OFFICE FI 971746        |                 |                                                                                     |
| 03-Nov-2004                     | WWE       | WIPO INFORMATION: ENTRY INTO NATIONAL PHASE FI 20041415     |                 |                                                                                     |
| 22-Jul-2003                     | WWG       | WIPO INFORMATION: GRANT IN NATIONAL OFFICE KR 1019970702789 |                 |                                                                                     |

## Document and Status

- 特許ファミリーとLegal statusの確認  
→権利状況にアクセス
- 特許明細 PDFダウンロード可

# Competitive Intelligence 特許レポート特徴

|                          |               |             |             |                   |
|--------------------------|---------------|-------------|-------------|-------------------|
| Companies and Drugs      | EXPIRY        |             |             |                   |
| Editorial Abstract       | EXPIRY DATES  |             |             |                   |
| Chemical Structures      | Patent Number | Authority   | Expiry Date | Status            |
| Claims                   | HK-01087714   | Hong Kong   | 11-Jul-2026 | BASED_ON_PRIORITY |
| Documents and Status     | AU-00710564   | Australia   | 27-Oct-2020 | AU70              |
| Expiry                   | IL-00137726   | Israel      | 07-Aug-2020 | BASED_ON_PRIORITY |
| Expiry Dates             | JP-03717934   | Japan       | 08-Apr-2020 | EXTENSION         |
| Supplementary Protection | EP-00788360   | Switzerland | 25-Jan-2020 | SPC               |
| Certificates             | IL-00133831   | Israel      | 30-Dec-2019 | BASED_ON_PRIORITY |
|                          | GR-03045186   | Greece      | 29-Apr-2019 | SPC               |

CLAIMS

07-JUL-2022 WO-2022147302-A1

CLAIMS: 1. A compound of Formula (I): or a prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein: Ring A is 7- to 10-membered heterocyclyl or 7- to 10-membered heteroaryl; Ring B is C 3 -C 10 cycloalkyl, 3- to 10-membered heterocyclyl, C 6 -C 10 aryl, or 5- to 10- membered heteroaryl; L is absent, -C(O)-, or -CH 2 -; each R 1 and R 3 is independently H, halogen, -CN, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, -O-C 1 -C 6 alkyl, -NH-C 1 -C 6 alkyl, or C 3 -C 7 cycloalkyl, wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are optionally substituted with one or more R 1a; R 1a is C 6 -C 10 aryl optionally substituted with one or more halogen, -CN, or -OH; R 2 is H, -(CH 2 ) n -N(R 2a )(R 2b ), -(CH 2 ) n -OH, -(CH 2 ) n -O(C 1 -C 6 alkyl), -(CH 2 ) n -O(C 6 -C 10 aryl), C 3 -C 7 cycloalkyl, 3- to 10-membered heterocyclyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 2b'; R 2a is H or C 1 -C 6 alkyl; R 2b is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, or C 3 -C 7 cycloalkyl, wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are optionally substituted with one or more R 2b', or R 2b is 3- to 10-membered heterocyclyl optionally substituted with one or more oxo or - (C 1 -C 6 alkyl)-OH, or R 2a and R 2b come together to form a 3- to 10-membered heterocyclyl optionally substituted with one or more R 2b'; R 2b' is oxo, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, - (CH 2 ) m -OR 2b'', -(CH 2 ) m -N(R 2b'')(R 2b'''), -(CH 2 ) m -C(O)OR 2b'', -C(O)R 2b'', -C(O)N(R 2b'')(R 2b'''), - N(R 2b'')C(O)R 2b'', C 3 -C 7 cycloalkyl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 2b''; R 2b'' is H, oxo, -CN, -OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 haloalkyl, wherein the alkyl, alkenyl, and alkynyl are optionally substituted with 3- to 10-membered heterocyclyl, wherein the heterocyclyl is optionally substituted with oxo; R 2b''' is H, C 1 -C 6 alkyl optionally substituted with one or more -C(O)OH, -OH or -NH 2, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, or -C(O)C 1 -C 6 alkyl; each R 4 or R 5 is independently H, -O-C 1 -C 6 alkyl, -NH-C 1 -C 6 alkyl, -NH-(5- to 10- membered heteroaryl), -NH-(C 6 -C 10 aryl), -NH-C(O)R 5a, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, or heteroaryl are optionally substituted with one or more R 5a, or R 4 and R 5 come together to form a C 4 -C 7 cycloalkyl or 4- to 10-membered heterocyclyl; R 5a is C 3 -C 7 cycloalkyl, 3- to 10-membered heterocyclyl, C 6 -C 10 aryl, or 5- to 10- membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 5a; R 5a is halogen, -CN, -(CH 2 ) p -N(R 5a')(R 5b1'), -O-C 1 -C 6 alkyl, -(CH 2 ) p -C 3 -C 7 cycloalkyl wherein the cycloalkyl is optionally substituted with one or more -C(O)OH, -OH or -NH 2, C 1 -C 6 alkyl optionally substituted with one or more halogen, -C(O)OH, -OH, or -NH 2, or 3- to 10-membered heterocyclyl optionally substituted with one or more -(C 1 -C 6 alkyl)-OH; R 5b1' is H or C 1 -C 6 alkyl; R 5a' is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 10-membered heterocyclyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl,

## Expiry


延長登録情報を収録→権利状況にアクセス

## Claims


請求項を確認

# Intellectual property landscape

## POWER BIによるライフサイエンス領域の特許分析



- ターゲットや技術に紐づく特許の出願数年次推移から注目されている開発領域を分析
- 国別に各特許の権利満了日をガントチャートで確認




## BIツールを活用した分析事例

- パイプライン全体像分析機能 Competitive Landscape Viewer
- ポートフォリオ分析機能 Virtual Merger

# パイプライン全体像分析機能 Competitive Landscape Viewer

治療疾患領域、作用メカニズム、技術の観点から競合パイプライン全体像を把握

- 作用メカニズムや疾患、技術など、特定の領域で開発中の全てのパイプラインの開発ステータスを把握する
- 自社のビジネス領域における新たな競合の脅威を同定する
- 単一の統合情報プラットフォームで競合情報全体を網羅する-開発試験、段階的な承認申請における規制、契約、特許等の情報をモニター



操作解説資料

<https://clarivate.com/cortellis/ja/download/69944/>

# Virtual merger

2つの企業を仮想合併させた際の  
ポートフォリオ分析が簡単に  
実施可能





# ユーザーサポートのご案内


# “?”のご活用

ログイン後に画面端に表示される  
「？」アイコンから様々なガイドを  
ご利用頂けます


- アップデートのお知らせ
- 使い方ガイド  
(日本語あり)
- 各種トレーニング資料 (日本語ページへのリンクあり)
- ユーザコミュニケーション  
ツールによるフィードバック



日本語  
サポートページ



機能強化・改善要望



各種お知らせや資料  
へのリンク

# ユーザーサポートご案内

## 日本語サポートサイト

<https://clarivate.com/cortellis/ja/learning/cortellis-training-home-1564/>

日本スタッフによる日本語マニュアル・資料をご用意。



ご活用ください!

## パブリックWebセミナー

<https://clarivate.com/cortellis/ja/training-webinars/>

ユーザーならどなたでも参加できるWebセミナーを年間を通じて開催。参加できなくても録画版を視聴できます。



## 顧客別・部署別講習会の提供

画一的な利用説明会ではなく、事前のヒアリングを経たユーザーニーズに沿ったデータベース講習会を開催しています。

## 製品内ガイドツアー

データベースの基本ワークフローの各ステップを解説するツアーでスムーズに使い始めていただけます。



## カスタマーケア

☎ 0800-170-5577(フリーダイヤル)  
(土日祝日を除く) 9:30~17:30  
✉ [ts.support.jp@clarivate.com](mailto:ts.support.jp@clarivate.com)

専門スタッフが対応。使い方、アクセスなどにお困りの際は、気軽に日本語で問合せが可能。

使い方等に関する  
ご質問はこちらに。



# Thank You

## About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://clarivate.com)

© 2023 Clarivate

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.